Breaks Categories: News

WednesdayNov 16, 2022 2:42 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Marks Key Step in Progress Toward Commercializing Medicinal Cannabis

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced the completion of its new laboratory located in Bogota, Colombia. Specializing in the manufacturing of compound formulations utilizing cannabis derivatives and traditional master formulas, Flora Lab 4 will become part of Flora’s group of laboratories. These include existing labs that produce cosmetics, phytotherapeutic products, dietary supplements, and cannabis extraction and transformation. “The completion of Flora Lab 4 is an important step in Flora Growth’s progress toward commercializing medicinal cannabis. This lab is built to produce prescription-grade medications and manufacture cannabis-based formulations,” said…

Continue Reading

WednesdayNov 16, 2022 2:00 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation to the treatment of neurodegenerative diseases; the new program will focus on two lead analogs to conduct studies using in vivo models to select the most appropriate candidate for clinical studies. The company anticipates that early preclinical…

Continue Reading

MondayNov 14, 2022 12:19 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Partners with 357 Company to Launch Cannabis Division

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is working with the 357 Company to launch 357’s Canna Logistics division. The new division is an expansion beyond 357’s Hemp Logistics segment, which ships federally legal hemp within the United States. According to the announcement, the new division will focus on logistics management and shipping of cannabis and hemp between countries where cannabis has been legalized. 357 is working to expand into international shipping of cannabis, hemp and industrial hemp; the cannabis export/import industry is new and poses significant potential for shipments of…

Continue Reading

MondayNov 14, 2022 12:04 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has reported its financial results for the first quarter of fiscal year 2023, ended Sept. 30, 2022. Highlights of the report included updates on the company’s pharmaceutical development programs, including INM-755 for the treatment of epidermolysis bullosa (“EB”) and INM-088 for the treatment of glaucoma. According to the report, enrollment and patient treatment in the company’s phase 2 clinical trial for INM-755 should be complete by the end of the year while the company continues to conduct key preclinical work including toxicology and GLP studies in…

Continue Reading

ThursdayNov 10, 2022 2:28 pm

CannabisNewsBreaks – Advanced Container Technologies Inc.’s (ACTX) GrowPods Allow Farmers to Spice It Up

Advanced Container Technologies (OTC: ACTX) offers unique controlled environment farms, GrowPods, which can allow growers to start cultivating in-demand, high-margin specialty herbs and spices. The U.S. market for fresh culinary herbs is growing. According to the U.S. Agency for International Development, popularity of leafy plants such as basil, cilantro and parsley that add flavor, aroma or garnish, increased 10% to 12% annually from 2004 to 2014 and has continued to climb. However, domestic field production does not meet demand, resulting in importation of nearly $300 million worth of leafy plants each year. In addition, domestically produced and imported goods face…

Continue Reading

ThursdayNov 10, 2022 2:18 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First-Ever Study Exploring Therapeutic Use of DehydraTECH-CBD in Dementia

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is starting a new study program — DEM-A22-1 — on Nov. 15, 2022. The study, a first for Lexaria, will evaluate whether LEXX’s DehydraTECH-processed cannabidiol (“CBD”) may have potential for therapeutic treatment for dementia. According to the announcement, Lexaria has previously shown the efficacy of DehydraTECH-CBD in studies focused on human hypertension; the studies showed no serious side effects. Lexaria is exploring the potential for dementia based on previous clinical studies that have established connections between hypertension and dementia: specifically, that individuals who have high blood pressure are more likely…

Continue Reading

ThursdayNov 10, 2022 1:57 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Reports Majority of Franchise Global Health (TSX.V: FGH) Shareholders Approve Acquisition

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is one step closer to completing its previously announced acquisition of Franchise Global Health (TSX.V: FGH). FLGC announced that holders of more than 73% of the outstanding shares of FGH have agreed to vote their shares in favor of Flora’s acquisition of FGH; the voting will take place during FGH’s special meeting of shareholders, scheduled for Dec. 13, 2022. The completion of the acquisition remains subject to customary closing conditions, including approval of the plan of arrangement by the Supreme Court of British Columbia…

Continue Reading

ThursdayNov 10, 2022 12:09 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that its CEO Eric A. Adams and SVP of Preclinical Research and Development Eric Hsu will present at Tribe Public’s upcoming webinar presentation and Q&A event. Titled “Exploring the Neuroprotective Qualities of Rare Cannabinoids,” the event is scheduled to begin at 8:30 a.m. Pacific Time on Nov. 17, 2022. Interested parties should visit https://cnw.fm/ebyJy to register for and join the complimentary, Zoom webinar-based event. Once registered, participants may begin forwarding their questions for InMed’s management to Tribe Public at…

Continue Reading

TuesdayNov 08, 2022 12:58 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that study program DIAB-A22-1 is expected to begin on schedule today. According to the announcement, this is Lexaria’s first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol (“CBD”) may potentially have therapeutic utility against diabetes. The company has evidenced the safety and efficacy of DehydraTECH-CBD in human hypertension studies. Strong connections exist between heart disease, hypertension and diabetes, with hypertension twice as frequent in diabetics and hypertensive patients at greater risk of developing diabetes. Diabetes, which prevents the body from making enough insulin and results in…

Continue Reading

TuesdayNov 01, 2022 1:26 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

Continue Reading